Explore how big data and machine learning are revolutionizing drug development risk assessment in this 36-minute lecture from Yale University. Delve into the challenges of identifying new drug targets and developing safe, effective medications, while examining the complexities of characterizing drug development risk. Learn how the combination of machine learning and data availability can provide more accurate and unbiased estimates of success probabilities in pharmaceutical research. Discover the approach developed and commercialized by Intelligencia Inc., currently utilized by top biopharmaceutical companies. Gain insights from speaker Vangelis Vergetis, PhD, co-founder and CEO of Epikast, as he shares his extensive experience in healthcare, technology, and data science, offering valuable perspectives on improving R&D productivity and resource allocation in the pharmaceutical industry.